Full-Time

Director of Operational Efficiency & Technology Innovation

MMS

MMS

1,001-5,000 employees

Regulatory compliance and data solutions provider

No salary listed

London, UK

In Person

Category
AI & Machine Learning (1)
Required Skills
Biometrics
Data Science
Machine Learning
Risk Management

Get referred to MMS

See people who can refer or advise you

Requirements
  • A minimum of 10 years of experience in technology innovation, operational excellence, digital transformation, artificial intelligence, or a related field.
  • Significant hands-on experience driving artificial intelligence strategy and implementing artificial intelligence technologies, artificial intelligence agents, automation, or machine learning solutions within an enterprise environment.
  • Strong understanding of artificial intelligence, machine learning, automation technologies, and their practical application to improve business operations.
  • Demonstrated ability to lead cross-functional initiatives and influence stakeholders across all levels of the organization.
  • Ability to anticipate and effectively resolve complex business and client challenges.
  • Demonstrated managerial and leadership experience with a proven ability to drive organizational change and innovation.
Responsibilities
  • Drive the evaluation, development, and implementation of artificial intelligence, machine learning, automation, and emerging technologies to improve operational efficiency, service delivery, and innovation across all MMS service lines.
  • Improve efficiency and quality through process optimization and automation, including cost savings, speed to delivery, enhanced quality, improved employee experience, and scalable operations.
  • Serve as a key opinion leader on the AI Steering Committee.
  • Partner with Quality, Regulatory, IT, and business leaders to establish artificial intelligence governance, risk management frameworks, validation approaches, and compliance with applicable regulations and industry standards.
  • Partner with operational service line leaders and the Data Science team to identify technology opportunities, drive artificial intelligence adoption, and lead change management initiatives across multidisciplinary teams, including Biometrics, Medical Writing, Pharmacovigilance, Regulatory, and other operational functions.
  • Represent MMS in industry consortiums, scientific conferences, client meetings, and strategic technology partnerships related to artificial intelligence, automation, and digital transformation.
Desired Qualifications
  • Experience within the pharmaceutical, biotechnology, contract research organization, healthcare, or another regulated industry.
  • Technical experience or understanding of clinical trial implementation, biometrics, or related operational functions.

MMS Holdings is a global contract research organization (CRO) focused on regulatory compliance and data-driven solutions for pharmaceutical and biotech sponsors. It delivers services such as regulatory submissions, clinical trial management, data analytics, and medical writing through a service-based model that relies on established processes and experienced advisors. Its work is contract-based, often long-term, aimed at helping clients meet regulatory requirements, run trials efficiently, and advance therapies under FDA guidance. The company differentiates itself with a science-first approach, a strong track record (97% client satisfaction), and involvement in complex areas like enabling MDMA-assisted therapy research, underscoring a commitment to high-quality, compliant outcomes for sponsors globally.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Canton, Ohio

Founded

2006

Get referred to MMS

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Datacise reached ACDM finalist status in January 2026, validating MMS's software strategy.
  • West Coast expansion before BIO 2026 targets venture-backed biotechs and faster sponsor acquisition.
  • I-ACT and pediatric-trials partnerships broaden MMS's therapeutic footprint and referral network.

What critics are saying

  • MMS still depends on sponsor-funded biotech budgets; trial delays hit revenue fast in 2026.
  • Private-equity ownership under Lindsay Goldberg pushes margin discipline before culture and retention.
  • Ascendancy in biometrics invites competition from IQVIA, Parexel, and Medidata on bigger accounts.

What makes MMS unique

  • Exploristics acquisition added KerusCloud and deep biostatistics, strengthening MMS's data science edge.
  • Ben Dudley became President in May 2026, sharpening global commercial and scientific execution.
  • Former FDA leaders Somya Dunn and other advisors deepen MMS's regulatory credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

20%

1 year growth

20%

2 year growth

20%
MMS Holdings
Feb 12th, 2025
MMS Acquires Exploristics for Data Science Expansion

MMS, a clinical research organization, has acquired Exploristics, a biostatistics and data science company. This acquisition enhances MMS' capabilities in advanced clinical trial design and data science, integrating Exploristics' KerusCloud® platform. The move expands MMS' global presence, particularly in Europe, and aims to optimize drug development strategies, reducing time and costs. Exploristics' CEO, Aiden Flynn, joins MMS as Senior VP, Head of Strategic Statistical Consulting.

TipRanks
Jan 29th, 2024
Orgenesis Inc Strikes Definitive Deal to Acquire Octomera LLC

On January 29, 2024, Orgenesis Inc. acquired all equity interests in Octomera LLC from MM OS Holdings, L.P., an affiliate of Metalmark Capital.

MMS Holdings
Apr 18th, 2023
MMS Named Great Place To Work In The UK

MMS Holdings Inc. plan to expand and grow in the UK and Europe to build on its teams and deliver value to its clients”

Applied Clinical Trials
Apr 14th, 2023
People and Business News – 4/23

EmVenio Research announced the appointment of Mark Mackenzie, MD, as chief medical officer.

Business Wire
Mar 21st, 2023
MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise | Business Wire

MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.